Earnings Insights · REGN · Q3 FY2026

Regeneron Q3 2026 Earnings: Sanofi Profit Share and Growth Brands Drive 36% Revenue Growth

By AlgovestIQ ResearchPublished

Share

Read Regeneron Pharmaceuticals’s results announcement (Form 8-K, filed Oct 30, 2026)

Key earnings findings

Regeneron Pharmaceuticals (REGN) Q3 FY2026 · results discussed on the earnings call · Form 8-K filed

  1. Regeneron Pharmaceuticals reported Q3 FY2026 revenue of $5.12B against the $4.58B analyst estimate, a 11.6% beat, and EPS of $20.07 against the $16.51 analyst estimate, a 21.6% beat.
  2. It expects 2027’s effective tax rate to face roughly 100 to 200 basis points of upward pressure relative to 2026.
  3. REGN closed at $927.89 on Oct 30, 2026, up 13.3% from $818.77 on Oct 29, 2026, the last close before the results were released.

Sources: Regeneron Pharmaceuticals results announcement (SEC), the Q3 FY2026 earnings call, and AlgovestIQ reported-results and market data. All references

Did Regeneron Pharmaceuticals beat earnings expectations?

Actual
Estimate
Surprise
Revenue
$5.12B
$4.58B
+11.6%
EPS
$20.07
$16.51
+21.6%
  • EPS has beaten the estimate in 6 of the most recent reported quarters.
  • Revenue surprise across the last 8 reported quarters has ranged from -6.8% to 12.4%.

Reported figures against analyst estimates, compiled from AlgovestIQ data.

Regeneron reported third-quarter revenue of $5.1B, up 36% year over year, while GAAP diluted EPS rose 35% to $18.45 and non-GAAP EPS increased 70% to $20.07. The largest driver was a sharp increase in Sanofi collaboration revenue following continued Dupixent growth and the end of the Sanofi Development Balance repayment.

The quarter reinforced Regeneron’s strength in immunology and oncology, with Dupixent, EYLEA HD, and Libtayo reaching record sales levels. However, the legacy EYLEA franchise remains under pressure from biosimilars and patient conversion to EYLEA HD, while higher R&D spending and a planned step-up in 2027 investment will limit how much of the current revenue growth translates into near-term margin expansion.

Earnings Snapshot

MetricReportedChange
Total revenue$5.1B+36%
GAAP net income$1.9B+33%
GAAP diluted EPS$18.45+35%
Non-GAAP net income$2.2B+67%
Non-GAAP diluted EPS$20.07+70%
Total net product sales$1.8B+14%
Sanofi collaboration revenue$2.7B+68%
EYLEA HD U.S. sales$699M+62%
EYLEA U.S. sales$400M-41%
Combined U.S. EYLEA HD and EYLEA sales$1.1B-1%
Libtayo global sales$550M+51%
GAAP R&D expense$1.8B+22%
GAAP gross margin on product sales82%Flat
Free cash flow, first nine months$2.9B-8%

The Bigger Story

The central development was not simply product-sales growth. Regeneron’s revenue mix shifted further toward collaboration economics, particularly its share of profits from Dupixent and other Sanofi-partnered antibodies.

Sanofi collaboration revenue rose 68% to $2.7B. Regeneron’s share of profits from the commercialization of partnered antibodies increased 77% to $2.6B, driven primarily by Dupixent’s growth and by the repayment of the Sanofi Development Balance at the end of the second quarter. That repayment meant Regeneron recorded its full share of collaboration profits during the third quarter rather than having revenue reduced to settle the balance.

This is a meaningful earnings tailwind, but it also underscores that a large portion of Regeneron’s growth is tied to the performance of a product whose sales are recorded by Sanofi. Dupixent remains a major value driver for Regeneron, but the company’s reported revenue increasingly reflects profit-sharing arrangements rather than only medicines sold directly by Regeneron.

The expanded Sanofi alliance also adds longer-term optionality. Regeneron received a $1.0B upfront payment in October for four next-generation, long-acting immunology antibodies and expects to recognize the full amount as Sanofi collaboration revenue in the fourth quarter. The company could receive up to another $7.0B in development, regulatory, and sales milestones, although those payments remain contingent on future progress.

Revenue and Operating Performance

Total product sales rose 14% to $1.8B, led by EYLEA HD and Libtayo. However, the growth did not fully offset continued erosion in the original EYLEA franchise.

EYLEA HD Is Growing, but the Franchise Is Still Contracting

U.S. EYLEA HD sales increased 62% to $699M, supported by higher demand and patient conversion from standard-dose EYLEA. Management said physician unit demand for EYLEA HD rose 20% sequentially, reflecting adoption of extended dosing intervals and prior label expansions.

The trade-off is that legacy EYLEA sales fell 41% to $400M as patients moved to EYLEA HD and as competitive pressure intensified. Combined U.S. sales of EYLEA HD and EYLEA declined 1% to $1.1B.

The franchise picture was weaker outside the United States. Combined global EYLEA HD and EYLEA sales fell 11% to $1.7B, with standard-dose EYLEA sales down 49%. Bayer collaboration revenue declined 23% to $267M, reflecting lower profit-sharing income from EYLEA sales outside the U.S.

Management expects EYLEA HD’s U.S. sales to grow sequentially by about 10% in the fourth quarter, although it also expects ongoing pricing pressure. An FDA decision on the EYLEA HD prefilled syringe is anticipated before year-end, and management expects approval could support further adoption in 2027.

Dupixent Remains the Primary Growth Engine

Dupixent global net sales, recorded by Sanofi, increased 35% to $6.5B. U.S. sales rose 40% to $5.1B, driven by demand across indications and favorable gross-to-net adjustments, according to Sanofi’s reported results.

Regeneron said more than 1.5 million patients are now being treated with Dupixent globally. The product is approved in nine type 2 inflammatory disease indications, creating a broad commercial base that supports Regeneron’s collaboration profit stream.

The durability of Dupixent growth remains central to the investment case. Its commercial reach is extensive, but the larger question is how long the product can sustain this growth rate as competitors develop new treatments in atopic dermatitis, asthma, and other inflammatory diseases.

Libtayo Continues to Scale

Libtayo global sales rose 51% to $550M, with U.S. sales up 81% to $396M. Growth was driven by higher demand, particularly in non-melanoma skin cancer and non-small cell lung cancer.

Management said Libtayo is the leading immunotherapy in U.S. non-melanoma skin cancers and the second most prescribed immunotherapy in non-small cell lung cancer. The recent approval in adjuvant cutaneous squamous cell carcinoma is contributing to growth, while a potential move to every-six-week dosing could improve patient convenience.

The European Commission is expected to decide on the extended dosing schedule in coming months, while the FDA has set a March 2027 action date for the U.S. supplemental application.

Profitability and Margins

GAAP net income increased 33% to $1.9B, and GAAP diluted EPS rose 35% to $18.45. Non-GAAP diluted EPS increased 70% to $20.07.

The difference between GAAP and non-GAAP EPS growth partly reflects an unusual comparison base. In the third quarter of 2025, Regeneron recorded substantially higher gains on marketable and other securities, which are excluded from its non-GAAP results. The prior-year quarter also included a $45M tax charge related to the enactment of the One Big Beautiful Bill Act.

R&D expense increased 22% on a GAAP basis to $1.8B and 23% on a non-GAAP basis to $1.7B. Regeneron attributed the increase to advancement of its clinical pipeline and manufacturing activity for product candidates. SG&A rose more modestly, with GAAP expense up 3% to $678M and non-GAAP expense up 9% to $588M.

GAAP and non-GAAP gross margin on product sales were unchanged at 82% and 86%, respectively. The stable quarterly margin profile is notable given the changing product mix, but full-year guidance now assumes lower gross margins than previously expected.

Other revenue increased 57% to $310M. That category included $253M from Regeneron’s share of ARCALYST profits and Ilaris royalties. Management said Ilaris royalty revenue included an approximately $60M cumulative catch-up adjustment that will not recur in the fourth quarter.

Demand, Customers and Pricing

Demand remained strong for EYLEA HD, Libtayo, and Dupixent, although the drivers differ across franchises.

For EYLEA HD, higher physician demand is offsetting lower pricing. Regeneron said EYLEA HD growth was partly offset by a lower net selling price, while legacy EYLEA faces continued volume pressure from biosimilars and patient conversion to the 8 mg formulation.

For Dupixent, management cited broad demand across indications and age groups, alongside favorable U.S. gross-to-net adjustments. The product’s commercial momentum is translating directly into higher collaboration profit for Regeneron.

Libtayo’s growth is volume-driven, with formulary progress and the adjuvant CSCC launch supporting uptake. Management expects continued gains in lung cancer market share and adoption in adjuvant CSCC.

What is Regeneron’s guidance for full-year 2026?

Regeneron updated its 2026 expense and margin outlook while maintaining its capital-expenditure and collaboration-cost expectations.

Management’s full-year guidance includes:

  • GAAP R&D expense: $6.6B to $6.735B
  • Non-GAAP R&D expense: $6.05B to $6.15B
  • GAAP SG&A expense: $2.73B to $2.86B
  • Non-GAAP SG&A expense: $2.4B to $2.5B
  • GAAP gross margin on product sales: approximately 80%
  • Non-GAAP gross margin on product sales: approximately 86%
  • GAAP cost of collaboration and contract manufacturing: $985M to $1.035B
  • Capital expenditures: $1.05B to $1.1B
  • GAAP effective tax rate: approximately 14%
  • Non-GAAP effective tax rate: approximately 15%

Management also expects 2027 R&D expense to rise by a mid-teens percentage from 2026 as the company advances registrational programs in multiple myeloma, anticoagulation, obesity, and other pipeline areas. It expects 2027’s effective tax rate to face roughly 100 to 200 basis points of upward pressure relative to 2026.

Near-term pipeline milestones include an FDA decision in November for cemdisiran in generalized myasthenia gravis, pivotal results in paroxysmal nocturnal hemoglobinuria by year-end, and an FDA decision for Ordspono in relapsed or refractory diffuse large B-cell lymphoma in February 2027.

Balance Sheet, Cash Flow and Capital

Regeneron ended the quarter with $18.9B in cash and marketable securities and $2.0B of long-term debt, or roughly $16.2B in net cash.

Free cash flow was $2.9B through the first nine months of 2026, down from $3.2B in the prior-year period. Operating cash flow declined modestly while capital expenditures rose to $771M from $650M.

The company repurchased $2.3B of stock, or 3.2 million shares, through the first nine months. Management expects approximately $3B of full-year repurchases, and $2.2B remained under existing repurchase authorizations as of September 30.

Regeneron also declared a quarterly cash dividend of $0.94 per share, payable in December.

What Investors Should Watch

1. EYLEA HD Growth Versus Legacy EYLEA Erosion

EYLEA HD is growing rapidly, but the combined U.S. retinal franchise declined 1% and global EYLEA franchise sales fell 11%. Sustained EYLEA HD demand and a successful prefilled-syringe launch would help stabilize the franchise, while continued biosimilar pressure could worsen the decline.

2. Dupixent Growth and Collaboration Profit Conversion

Dupixent’s 35% global sales growth remains the most important earnings driver. Investors should monitor whether the product can sustain broad demand growth as Regeneron now receives its full share of Sanofi collaboration profits.

3. R&D Spending and Pipeline Productivity

Management expects mid-teens R&D growth in 2027. That spending is justified only if the pipeline delivers clinically differentiated products and progresses into registrational development, particularly in gMG, PNH, oncology, anticoagulation, obesity, POTS, and metabolic liver disease.

4. Fourth-Quarter Revenue Quality

The $1.0B Sanofi upfront payment will materially lift fourth-quarter collaboration revenue, but it is a one-time payment. Investors should distinguish that recognition from underlying commercial growth in Dupixent, Libtayo, and EYLEA HD.

5. Early Clinical Data in Large New Markets

Regeneron highlighted preliminary results for its CIDEB-targeting RNAi therapy in metabolic liver disease, ubamatamab in ovarian cancer, and REGN751 in POTS. These programs could broaden the company’s growth profile, but their current data remain early-stage and require validation in larger studies.

AlgovestIQ Takeaway

Regeneron delivered a strong quarter, supported by three clear commercial assets: Dupixent, EYLEA HD, and Libtayo. The most important financial change was the full recognition of Regeneron’s share of Sanofi collaboration profits after the Development Balance was repaid, which materially improved revenue and earnings growth.

The quality of that growth is mixed but broadly constructive. Dupixent and Libtayo are expanding on rising demand, while EYLEA HD is successfully gaining adoption. Yet EYLEA HD is also replacing a declining legacy EYLEA business, and the combined franchise remains under competitive and pricing pressure.

The expanded Sanofi collaboration extends Regeneron’s immunology opportunity beyond Dupixent, while the $1.0B upfront payment provides a near-term fourth-quarter revenue benefit. The more important strategic question is whether the next-generation antibodies can eventually preserve or expand the company’s leadership in type 2 inflammation as competitive products emerge.

Regeneron has the balance sheet to fund its pipeline and continue repurchases, but it is also signaling a substantial increase in R&D investment next year. The key evidence for the long-term thesis will be whether upcoming regulatory decisions and clinical readouts translate this investment into additional durable commercial franchises rather than a larger cost base.

How did REGN stock react?

REGN closed at $927.89 on Oct 30, 2026, up 13.3% from $818.77 on Oct 29, 2026, the last close before the results were released.

SessionCloseChange
Oct 29, 2026 (before release)$818.77—
Oct 30, 2026$927.89+13.3%
Nov 2, 2026$961.26+17.4%

Closing prices from AlgovestIQ market data. A move around a report also reflects the wider market.

More from this earnings season

References

  1. Management commentary, analyst questions and outlook discussed on the call. Source: Regeneron Pharmaceuticals Q3 FY2026 earnings call transcript, as of Oct 30, 2026.
  2. Reported results, segment figures and guidance from the company's results announcement. Source: Regeneron Pharmaceuticals Form 8-K, Item 2.02 (SEC EDGAR), as of Oct 30, 2026.
  3. Reported revenue and EPS against analyst estimates, and the reported quarterly series. Source: AlgovestIQ reported-results data, as of Oct 30, 2026.

AI-generated analysis based on company-reported earnings data and earnings-call materials. Not investment advice.